Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Steroid-Sparing cocktail tame chemo nausea?

NCT ID NCT07699276

Symptom relief Sponsor: Mahidol University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of olanzapine and ondansetron can prevent nausea and vomiting caused by high-dose cisplatin chemotherapy in people with solid tumors. The approach aims to reduce steroid use by omitting dexamethasone on days 2 through 4. The study enrolls adults receiving their first cycle of cisplatin at a dose of at least 50 mg/m².

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
olanzapine and ondansetron (with dexamethasone sparing)
What this could lead to
If successful, this could offer a way to prevent chemotherapy-induced nausea and vomiting while reducing steroid use, potentially lowering side effects.
What could go wrong
This is a small, single-arm phase 2 study, so results may not apply broadly. The steroid-sparing approach might be less effective than standard care, and olanzapine can cause drowsiness or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 95 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * histologically confirmed solid malignancy * scheduled for first cycle of cisplatin at dosage of at least 50 mg/m2 Exclusion Criteria: * pregnancy * pelvic or abdominal radiation within 4 weeks * uncontrolled brain metastasis * other moderate or high emetic risk chemotherapy on day 2-5 * untreated gut obstruction * known allergy or severe adverse effect from palonosetron or olanzapine * AST/ ALT \> 2.5x or serum creatinine clearance less than 50 ml/min

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer (solid tumors) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer (solid tumors) Cisplatin Olanzapine Vomiting

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Medicine Siriraj Hospital, Mahidol University

    RECRUITING

    Bangkok, 10700, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.